Adding Centanafadine to Schedule III

You might care about this because the Drug Enforcement Administration is placing a new medication called centanafadine into Schedule III of the Controlled Substances Act. Centanafadine is sold under the brand name Simtriyo and helps treat attention-deficit and hyperactivity disorder in adults and children who are at least six years old and weigh at least twenty kilograms. The Food and Drug Administration approved this medicine on July 24, 2026. Following that approval, the Department of Health and Human Services evaluated the drug and recommended placing it under federal control because it has some potential for abuse. The Drug Enforcement Administration is now issuing an interim final rule to put this scheduling decision into effect immediately. The document explains how the public can submit comments or request a hearing on this rule before the end of November 2026. This action follows a fast-track process required by federal law for newly approved medical therapies that affect the central nervous system.

This rule matters because it shows how federal agencies handle newly approved medications that carry a risk of abuse. The Food and Drug Administration approved centanafadine to treat attention issues. At the same time, because the drug acts on the central nervous system in ways similar to other controlled substances, federal drug laws require putting it into a restricted category. The process uses a special fast-track rule passed in 2015. This rule lets the Drug Enforcement Administration issue an interim final rule right away while still allowing people to share feedback. The decision relies on a detailed eight-factor analysis of the drug's medical use, abuse potential, and risk of dependence. This balances getting helpful new medicines to patients quickly with keeping proper controls over substances that could be misused.

This document will interest doctors, pharmacists, and medical researchers who work with attention-deficit and hyperactivity disorder treatments. Pharmaceutical companies and healthcare providers should also pay attention to how new drugs receive their federal schedules. Patients and parents who use these medications may want to know how the government regulates them. Legal professionals and policy experts who study drug control laws will find the application of the fast-track scheduling process useful to review.